Abstract
ABCG2 encodes the mitoxantrone resistance protein (MXR, BCRP), an ATP-binding cassette (ABC) efflux membrane transporter. Computational analysis of the ~300 kb region of DNA surrounding ABCG2 (chr4:88911376-89220011, hg19) identified 30 regions with potential cisregulatory capabilities. These putative regulatory regions were tested for their enhancer and suppressor activity in a human liver cell line using luciferase reporter assays. The in vitro enhancer and suppressor assays identified four regions that decreased gene expression and five regions that increased expression >1.6-fold. Four of five human hepatic in vitro enhancers were confirmed as in vivo liver enhancers using the mouse hydrodynamic tail vein injection assay.
Two of the in vivo liver enhancers (ABCG2RE1 and ABCG2RE9) responded to 17β-estradiol or rifampin in human cell lines, and ABCG2RE9 had ChIP-seq evidence to support the binding of several transcription factors and the transcriptional coactivator p300 in human hepatocytes. This study identified genomic regions surrounding human ABCG2 that can function as regulatory elements, some with the capacity to alter gene expression upon environmental stimulus. The results from this research will drive future investigations of interindividual variation in ABCG2 expression and function that contribute to differences in drug response.
Introduction
The mitoxantrone resistance protein (MXR; BCRP; ABCG2) is an efflux membrane transporter expressed apically in selected tissues, including liver, kidney, breast and intestine (Robey et al., 2009) . Transport activity, tissue distribution and cellular localization of MXR suggest it plays a pivotal role in endogenous substrate disposition and protection from xenobiotics (Jonker et al., 2005; Robey et al., 2009; Noguchi et al., 2009 ). In the liver, MXR is highly expressed on the canalicular membrane, where it transports substrates and their conjugates into the bile, increasing their elimination from the body (Maliepaard et al., 2001 ).
Susceptibility to drug-induced side effects has been linked to hepatic MXR expression and coding and non-coding single nucleotide polymorphisms (SNPs) in ABCG2, the gene encoding MXR (Poonkuzhali et al., 2008; Mo and J-T Zhang, 2012; Prasad et al., 2013) . Therefore, understanding the mechanisms regulating hepatic expression of MXR is necessary to elucidate individual susceptibility to cancer progression and drug side effects. et al., 2001 ) and has significant tissue-specific variability, including in intestine (Zamber et al., 2003; Urquhart et al., 2008) , liver (Poonkuzhali et al., 2008) and blast cells (Ross et al., 2000) . The ability to alter phase I-III expression in response to xenobiotic or toxin exposure is an important mechanism for detoxification. ABCG2 expression is altered by many stimuli, including hypoxia (Cheng and To, 2012) , inflammation (Pradhan et al., 2010) , hormones (Y Zhang et al., 2006; H Wang et al., 2007) and nutrients (Lemos et al., 2008; . Additionally, ABCG2 expression is modulated by nuclear receptor ligands including rifampin and estrogen (Ee et al., 2004; Jigorel et al., 2006) , indicating several enhancer elements are important for altering ABCG2 expression in different contexts. Nuclear response elements (NREs) in the proximal promoter of ABCG2 contribute
ABCG2 expression varies between tissues (Maliepaard
minimally to ABCG2 expression since methylation of a CpG island over the ABCG2 promoter blocks nuclear receptors access to their recognition sequence (Wiench et al., 2011; Mo and J-T Zhang, 2012) .
Additionally, nuclear receptors prefer binding to cis-elements over proximal promoters (Wiench et al., 2011) , making cis-elements important for nuclear receptor response. With the availability of genetic and tissue expression databases, the ability to interpret and correlate expression data to genetic variation and drug response or toxicity depends on identification of constitutive and inducible regulatory elements (Smith et al., 2012) . The studies described here test the hypothesis that there are cis-regulatory elements in the human ABCG2 gene locus that are active in vivo and aim to identify and characterize those regulatory regions both in vitro and in vivo.
Liver-specific enhancers of transporter genes, such as ABCB11 and SLCO1A2, have been identified by analysis of evolutionary conservation and prediction of conserved transcription factor binding sites (TFBS) (Pennacchio et al., 2007; Kim et al., 2009) . Studies have focused on sequence conservation of non-coding regions because many developmental enhancers, tissuespecific enhancers and nuclear receptor response elements are unchanged through different species (Ahituv et al., 2004; Woolfe et al., 2005; Pennacchio et al., 2006; Loots, 2008; So et al., 2008) . However, not all enhancer regions are conserved (King et al., 2007) . Since cisregulatory elements contain binding sites for multiple transcription factors, non-conserved regulatory elements could be identified by transcription factor clusters (So et al., 2007; Q Wang et al., 2007; Weltmeier and Borlak, 2011) . Thus, identifying cis-regulatory elements, especially for tissue-specific absorption, distribution, metabolism and excretion genes, could be achieved
by combining complementary genomic data sets that include evolutionary conservation and both conserved and non-conserved TFBS clusters.
In this study, putative cis-regulatory elements in the ABCG2 locus were identified by layered in silico analysis incorporating conserved sequence and TFBS predictions, combined with clustering of non-conserved TFBS. Regions with predictions for, or ChIP-seq evidence of, hepatic specific transcription factor binding were prioritized. Putative regulatory regions were cloned into enhancer or suppressor luciferase vectors, previously validated for identification of clinically correlated human liver enhancer variants (Kim et al., 2009; Matsson et al., 2011) , and their activity assayed in transiently transfected cell lines of liver, kidney, intestine and breast origin. Positive in vitro enhancer elements were screened for in vivo liver enhancer activity through hydrodynamic tail vein injection adapted for liver enhancer screening (Liu et al., 1999; Kim et al., 2009; Kim and Ahituv, 2013 (Goodwin et al., 1999) In silico analysis of the ABCG2 locus. The ABCG2 gene locus, defined as a ~300,000
bp region stretching one gene upstream (PPM1K) and downstream (PKD2) of ABCG2
(chr4:88911376-89220011, hg19), was scanned for regions >100 bp and ≥ 70% conservation of human to mouse using the Evolutionary Conserved Region (ECR) and Vista browsers (Ovcharenko et al., 2004; Frazer et al., 2004) . Conservation alignments from the ECR Browser were submitted to rVista for identification of conserved TFBS using all vertebrate transcription factor matrices from TRANSFAC professional (Wingender et al., 2000; Loots and Ovcharenko, 2004) . Regardless of conservation, the ABCG2 locus was examined for cluster regions (CR) of predicted TFBS, using the default setting of the Cister program (Frith et al., 2001 (Wingender et al., 2000) . Regions consisting of repeat, coding elements or gene promoters were eliminated from further analysis and overlapping regions from the conservation and Cister plot analyses were combined into single putative regulatory regions.
The top 30 putative regulatory regions were determined based on their percent identity human to mouse, the number of predicted TFBS per length of region, and total number of TFBS with extra weight given to TFBS associated with ABCG2 and liver or kidney gene expression (Supplementary Table 1 ). Extra weight was also given to regions with ChIP-seq data supporting association with transcription factors, histone 3 lysine 27 acetylation, histone 3 lysine 4 methylation (H3K4Me) and DNaseI sensitivity from TRANSFAC and the Encyclopedia of DNA Elements (ENCODE) databases (Wingender et al., 2000; Consortium, 2011 
XhoI (reverse primers) for all regions except ABCG2RE1, for which NheI (forward primer) and HindIII (reverse primer) were used, to ensure that the anti-strand sequence of the enhancer element would be oriented in the same manner as the element is to the ABCG2 promoter (Supplemental Table 2 ). The region of interest was amplified from human placenta genomic DNA using PfuTurbo DNA polymerase, gel purified and cloned into the pGL4.23 luciferase vector. Endotoxin-free DNA for the selected enhancer plasmids, empty pGL4.23, ApoE-pGL4.23 (Simonet et al., 1993) , pGL3-promoter with and without suppressor elements, pGL4.11b with and without the ABCG2 promoter, pGL4.13, hPXR-pcDNA3.1 and pGL4.74 vectors (Supplemental Table 3 ) were isolated using the GenElute HP Endotoxin-Free Maxiprep Kit following the manufacturer's protocol. For follow-up studies on suppressive elements, regions were re-amplified from the pGL4.23 vectors and cloned, using the same restriction sites, into the pGL3-promoter vector. Plasmids were sequenced to verify their identity and orientation in the luciferase vectors.
Cell culture and transfections. HEK293T/17, HCT116 and HepG2 cell lines were grown in high-glucose DMEM supplemented with 10% FBS, 100 U/mL of penicillin and 0.1 mg/mL of streptomycin. The MCF-7 cell line was grown in IMEM without phenol red, supplemented with 10% FBS, 100 U/mL of penicillin and 0.1 mg/mL of streptomycin; for use in the nuclear receptor ligand assays, the 10% FBS was charcoal stripped. All cell lines were grown in a 5% CO 2 incubator at 37°C. For the in vitro luciferase assays, the HEK293T/17, HepG2 and Mouse hydrodynamic tail vein enhancer assay. Positive in vitro enhancer elements were screened for in vivo liver enhancer activity using the mouse hydrodynamic tail vein injection adapted for enhancer element screening (Liu et al., 1999; Kim et al., 2009; Kim and Ahituv, 2013) . Each plasmid was injected into the tail vein of 4-5 mice using the TransIT EE In Vivo Gene Delivery System following the manufacturer's protocol. Briefly, 10 μ g of pGL4.23
vector with or without enhancer element, or the ApoE positive control liver enhancer (Simonet et al., 1993) , along with 2 μ g of pGL4.74 were injected into the tail vein of male CD1 mice (Charles River). After 24 hr, mice were euthanized and their livers harvested and homogenized in passive lysis buffer, followed by centrifugation at 4°C for 30 min at 21,000 g. The supernatant was diluted 1:20 with lysis buffer and measured for firefly and Renilla luciferase activity using the Dual-luciferase ® reporter assay system according to the manufacturer's protocol in a Synergy
mouse work was done following a protocol approved by the University of California San
Francisco Institutional Animal Care and Use Committee.
Nuclear receptor ligand treatment. The rifampin and 17β-estradiol (E 2 ) assays were adapted from previously published protocols (Goodwin et al., 1999; Ee et al., 2004; Chen et al., 2004; H Wang et al., 2006; Tan et al., 2011) . A plasmid with the XREM region that induces CYP3A4 expression upon rifampin treatment and an ABCG2 promoter construct that includes a known estrogen response element (ERE) were used as positive controls (Goodwin et al., 1999; Ee et al., 2004; Chen et al., 2004; H Wang et al., 2006; Tan et al., 2011 
Results Identification of high priority putative cis-regulatory elements. A list of 30 high priority elements (Table 1) was generated by the in silico analysis of the ABCG2 gene locus. Figure 1 illustrates a snapshot of evolutionary conservation, clustering of predicted cis-elements from Cister plot and ChIP-seq data available from ENCODE and TRANSFAC databases (Wingender et al., 2000; Frith et al., 2001; Consortium, 2011) . There were five regions that appeared in both the evolutionary conservation and Cister plot analyses, all of which were tested for enhancer activity. Also included were regions with preliminary ENCODE ChIP-seq data, for example ABCG2RE8 had FOXA1 and GATA3 peaks in T-47D cells and p300 in HeLa cells and ABCG2RE23 had CTCF peaks in many cell lines including HepG2 (Supplemental Figure 1) .
The high priority putative enhancer elements were located throughout the ABCG2 gene locus and ranged from 174-1909 bp (Table 1) . These regions were screened for in vitro enhancer activity.
In vitro enhancer and suppressor identification. The 30 high priority putative enhancer elements (Table 1) 
other tissues, they were also screened in HEK293T (kidney), HCT116 (intestine) and MCF-7 Table 1 ). Nine regions exhibited a 75%
decrease in luciferase activity in one cell line and at least a 50% decrease in two additional cell lines, and these were selected for follow-up in a suppressor assay. The ABCG2RE30 region, which was suppressive in two cell lines, was also chosen for follow-up because it exhibited enhancer activity in the renal cell line. HepG2 suppressor activity for four out of ten selected regions was confirmed by cloning into the pGL3-promoter vector, transfecting into the HepG2 cell line and measuring the resulting luciferase activity relative to empty vector (Figure 3 ).
pGL3-promoter is a firefly luciferase vector designed to accept a putative suppressor element upstream of the strong SV40 promoter; without a suppressor this promoter drives strong expression of luciferase. Since regions could potentially have tissue-specific suppressor activity, they were also screened in kidney, intestinal and breast cell lines. ABCG2RE7 was the strongest and most consistent suppressor, with > 75% decrease in luciferase activity in HepG2 and HCT116 cells. In HEK293T and MCF-7 cells, ABCG2RE7 also had > 50% decrease in luciferase activity (Supplemental Figure 3) . The ABCG2RE11, ABCG2RE29 and ABCG2RE30
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also had significant suppressor activity in the HepG2 cell line. Eleven genomic regions (37%)
showed enhancer activity and seven showed suppressor activity (23%) in at least one of the four cell lines, including ABCG2RE30, which had enhancer activity in HEK293 cells and suppressor activity in the HepG2 and HCT116 cell lines. Thus, a total of seventeen regions (57%) had significant regulatory activity in vitro.
In vivo enhancer activity. The five HepG2 in vitro enhancers were tested for in vivo activity in mice using the hydrodynamic tail vein injection technique (Kim and Ahituv, 2013) .
The ApoE liver enhancer (Simonet et al., 1993; Kim et al., 2009) Figure 4) . Overall the strongest in vivo enhancer was the ABCG2RE1 region; it had consistent activation over 120-fold, which is almost three times that of the positive ApoE control.
Nuclear receptor ligand response. The ability of ABCG2RE9 activity to respond to the PXR ligand rifampin or an estrogen receptor (ER) ligand 17β-estradiol was tested in transiently transfected HepG2 and MCF-7 cells, respectively. ABCG2RE9 had a 3-fold induction of its basal enhancer activity with rifampin treatment ( Figure 5A , Table 1 activity of the ABCG2RE9 region was reduced ~50% upon treatment with 17β-estradiol ( Figure   5B , Table 1 ). Additionally, eight regions with both in vitro enhancer activity in at least one cell line and bioinformatic evidence that either PXR or ER bound to it (data not shown), were tested for their response to rifampin and 17β-estradiol. One additional enhancer region was responsive to rifampin and three showed altered activity in response to 17β-estradiol (Supplemental Figure   5 ).
Transcription factor binding via ChIP-seq. The ABCG2RE9 enhancer has extensive transcriptional marks in ENCODE, including H3K4Me, DNaseI sensitivity clusters and many transcription factor ChIP-seq peaks in HepG2, including HNF4α, HNF4γ, retinoid X receptor (RXR) and p300 ( Figure 6 ). Specifically for these studies, FOXA1, a dimer partner of ER and RXRα, binds to ABCG2RE9. A ChIP-seq experiment by our laboratories (Smith et al., 2014) showed that p300 binds ABCG2RE9 in human primary hepatocytes treated both with and without rifampin, providing strong evidence that this is a transcriptionally active region in human liver ( Figure 6 ). The ABCG2RE8 and ABCG2RE23 putative enhancer elements also have ENCODE ChIP-seq data supporting transcription factor binding to these regions (Supplemental Figure 1) .
Discussion
These studies provide strong evidence in support of ABCG2RE9 as a nuclear receptor responsive element and cis-regulatory enhancer. Aside from NREs in the ABCG2 proximal promoter, very little is known about the transcriptional regulation of ABCG2. Regulatory control of MXR expression gives cells the ability to adapt to elevated or reduced levels of substrates. would affect drug elimination and thus pharmacokinetics. Characterizing hepatic regulation of ABCG2 is important in understanding how expression impacts both systemic and target site drug exposure.
In the present study, regulatory elements in the ABCG2 gene locus were identified and characterized through in silico, in vitro and in vivo methods. Through our in silico analysis, considering DNA and TFBS conservation between human and mice, transcription factor clustering and ChIP-seq data, we chose thirty high priority putative regulatory regions to test for transporter enhancer screen which utilized conservation and liver-specific TFBS as screening criteria, suggesting that the addition of in vitro cell-based screening or consideration of ChIP-seq data could improve the selection process for in vivo enhancer assays (Kim et al., 2009) . In general, enhancer activity in non-hepatic cells was not predictive of in vivo liver regulatory activity; one exception was the strongest in vivo liver enhancer (ABCG2RE1) which was inactive in liver cells, but was active in kidney, intestine and breast cell lines.
In vivo liver enhancer activity ranged from >120-fold activation (ABCG2RE1), three times that of the positive ApoE control, to 2.45-fold (ABCG2RE6); the remaining enhancers showed 5-to 16.5-fold relative activation. This degree of activation is in the range of the strong enhancer elements previously discovered for membrane transporters (Kim et al., 2009) . Three of the in vivo enhancers were within ABCG2 introns (ABCG2RE8 (intron 10), ABCG2RE9 (intron 9) and ABCG2RE14 (intron 1)), consistent with the finding that 40% of enhancers are within intronic regions (Heintzman et al., 2009 ). An in vivo enhancer (ABCG2RE26) encompassing exon 4 of PPM1K was also identified. Since exon 4 of PPM1K is relatively short, ABCG2RE26
was not excluded from our analysis because it also had numerous conserved and non-conserved predicted TFBS (data not shown). There are other examples of coding exons working as an enhancer to regulate the tissue-specific expression of a neighboring gene that were identified though ChIP-seq datasets (Birnbaum et al., 2012) . However, these examples have been infrequent, since in silico pipelines to identify conserved enhancer elements often eliminate coding regions under the assumption that they are conserved to preserve protein function, not due to cis-regulatory activity. These data illustrate that the addition of TFBS clustering, regardless of conservation or genomic region, could improve the enhancer selection process.
In order to investigate possible mechanisms driving the in vivo activity of enhancers, the ENCODE and TRANSFAC databases were mined for ChIP-seq data or predicted sites of transcription factor binding. TRANSFAC analysis of ABCG2RE1 predicted binding sites for constitutive androstane receptor, liver X receptor, PXR, vitamin D receptor and the aryl hydrocarbon receptor (data not shown). The in vitro enhancer activity of ABCG2RE1 was increased by the PXR ligand rifampin, indicating it has both constitutive and inducible enhancer activity. The ABCG2RE1 enhancer is ~4000 bp upstream of the PKD2 promoter and could be regulating the expression of PKD2, or be working as a loci enhancer element to regulate the expression of PKD2, PPM1K and/or ABGC2 in the kidney where they are all expressed.
ENCODE analysis found ChIP-seq signals for many transcription factors bound to the ABCG2RE9 region in liver cells, including RXRα and HNF4α. Both transcription factors are important in liver gene expression, and they interact with each other and with ERα (Lee et al., 1998; Schrem et al., 2002; Germain et al., 2006) . While CAR and PXR crosstalk with FOXA2
(another transcription factor that binds ABCG2RE9) to regulate hepatic genes (Konno et al., 2008) , the presence of GR, FOXA1, RXRα and p300 ChIP-seq signals, and the current data showing ABCG2RE9 responds to both PXR and ER ligands, indicate a likely role of this regulatory region in hormone response and possibly the expression of ABCG2 in the intestine, liver and placenta.
Some experiments in the ENCODE ChIP-seq database include before and after treatment with nuclear receptor ligands, providing an excellent resource for future regulatory element searches (Consortium, 2011) . It is worth noting that not all of the regions with ChIP-seq data were enhancers. ABCG2RE23 for example has many ChIP-seq peaks, especially strong and reproducible signals for CTCF (data not shown), but showed neither enhancer nor suppressor This article has not been copyedited and formatted. The final version may differ from this version. 
activity in most of the cell lines. This could be because CTCF can act as a general transcription factor, but it is best characterized for its ability to act as an insulator and modulator of chromatin structure (Phillips and Corces, 2009 ). The highest activity in vivo enhancer, ABCG2RE1, was devoid of ChIP-seq marks, but many transcription factors have either not been characterized or do not have reliable antibodies for use in ChIP-seq experiments, thus restricting interpretation of data in ENCODE.
Many NREs work in coordination with other transcription factors, like p300, to remodel chromatin, and the chromatin context is extremely important to transcription factor activity (Wiench et al., 2011) . Without the complex chromatin context, which was not assayed in our study, and the possibility that certain transcription factors are absent in the studied cell lines, some of the putative regions could still be in vivo cis-regulatory elements. This is most evident from the results of the ABCG2RE1 regulatory region, which had weak activity in vitro yet the strongest activity in vivo. Similarly, ABCG2RE6 had strong in vitro activity yet weak activity detected in vivo. Other limitations of the hydrodynamic tail vein assay include discordance between mouse and human TFBS, inability to detect nuclear factor response elements without the ligand present, and the limited ability to detect enhancer activity outside the liver. Additional induction assays would be needed to detect regulatory elements that are active only with drug treatment, and evaluation of enhancer regions in other model systems such as zebrafish might be useful to confirm non-liver enhancer activity. Potential tissue specific regulatory elements are highlighted in Supplemental Table 2 . Although individual steps of the screening pipeline have limitations, taken together they robustly identified several cis-regulatory elements with in vivo liver enhancer activity in the ABCG2 gene locus that are strongly supported by ChIP-seq data.
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